Article Text

Download PDFPDF

#509 Multicenter real-world experiences of PARPi rechallenge in patients with ovarian cancer in China
  1. Jin Li1,
  2. Feng Shao2,
  3. Lingjun Zhao3,
  4. Fei Zheng4,
  5. Hua Zhu5,
  6. Enchun Li6,
  7. Wei Zhou7,
  8. Guorong Yao8,
  9. Jie Liu9,
  10. Jianxiao Zheng10,
  11. Shan Pan11,
  12. Yue Zhang12 and
  13. Xiaohua Wu1
  1. 1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
  2. 2Gynecologic Surgical Department, Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Hangzhou, China
  3. 3Department of Gynecology, Ningbo Women and Children’s Hospital, Ningbo, China
  4. 4Department of Gynecology, Ningbo No.2 Hospital, Ningbo, China
  5. 5Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  6. 6Department of Gynecology, Women’s Hospital School of Medicine Zhejiang University, Hangzhou, China
  7. 7Department of Gynecology, Taizhou Hospital of Zhejiang Province, Taizhou, China
  8. 8Department of Integrated Chinese and Western Medicine, Huzhou Central Hospital, Huzhou, China
  9. 9Department of Gynecology, Jinhua People’s Hospital, Jinhua, China
  10. 10Department of Integrated Chinese and Western Medicine, Yueqing People’s Hospital, Wenzhou, China
  11. 11Department of Gynecology, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, China
  12. 12Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China


Introduction/Background The OReO/ENGOT Ov-38 trial showed maintenance olaparib rechallenge improved progression-free survival (PFS) compared with placebo. However, subpopulation benefit more from Poly (ADP-ribose) polymeraseinhibitors (PARPi) rechallenge was unclear. The objective of this real-world study is to evaluate the effectiveness, safety and explore benefit population of PARPi rechallenge in China.

Methodology This multi-center, non-interventional study included patients with PARPi-treated recurrent ovarian cancer who rechallenged PARPi as maintenance therapy or salvage treatment at 12 institutions between June 2019 and March 2023. Patients‘ demographics and outcomes were analyzed.

Results Seventy patients were included, and the median follow-up time was 13.0 months (table 1). Fifty-six (80%, 56/70) patients received PARPi as maintenance after maintenance therapy. The median PFS (mPFS) was 10.6 months (95% confidence interval [CI], 7.1–12.0) with first PARPi (PARPi1) and 8.6 months (95% CI, 5.3–13.0) with PARPi retreatment (PARPi2). 32.1% (18/56) patients were BRCA1/2 mutated, the PFS were not significantly different from BRCA wild-type or unknown patients (BRCAm vs. BRCAwt or unknown, HR=0.997 [95%CI: 0.480–2.072], P=0.9935). 87.5% (39/56) of patients switched to other PARPi when rechallenging. Patients switched to other PARPi rechallenging had numerically longer mPFS compared with those didn’t switch (mPFS: 8.6 vs. 7.7 months; HR=0.820 [95%CI: 0.394–1.707], P=0.5958). Overall, 4.3% (3/70) discontinued PARPi2 due to adverse events, most commonly due to hematologic adverse events.

Abstract #509 Table 1

Patients' characteristics

Conclusion Our study is the first multicenter real-world study to evaluate the rechallenge of PARPi in ovarian cancerpatients in China. There is a pressing need to identify biomarkers except BRCA to select appropriate patients for PARPi rechallenge.

Disclosures The authors have no potential conflict of interest to report.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.